Geode Capital Management LLC Sells 7,375 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB)

Geode Capital Management LLC lessened its holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 13.6% in the third quarter, Holdings Channel reports. The institutional investor owned 47,034 shares of the biopharmaceutical company’s stock after selling 7,375 shares during the period. Geode Capital Management LLC’s holdings in Assembly Biosciences were worth $712,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ASMB. Armistice Capital LLC acquired a new stake in Assembly Biosciences during the 2nd quarter valued at approximately $6,421,000. Renaissance Technologies LLC increased its position in Assembly Biosciences by 39.2% during the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 15,451 shares during the period. FMR LLC increased its position in Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares during the period. Finally, Acadian Asset Management LLC increased its position in Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 7,690 shares during the period. Institutional investors own 19.92% of the company’s stock.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of Assembly Biosciences stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.10% of the company’s stock.

Assembly Biosciences Stock Down 7.8 %

Shares of ASMB stock opened at $15.62 on Friday. Assembly Biosciences, Inc. has a 52 week low of $9.12 and a 52 week high of $19.93. The firm has a 50 day moving average of $16.00 and a 200-day moving average of $15.68.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Jefferies Financial Group raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and increased their target price for the company from $2.00 to $35.00 in a research report on Friday, September 20th. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.